Menstrual Blood Stem Cells in Poor Ovarian Responders

Status Completed

Clinical Trial Summary

In this controlled trial, poor ovarian responder women will be treated with transplantation of autologous menstrual blood stem cells. The investigators will attempt to assess the safety and efficacy of this procedure for the treatment of infertility in POR patients compared to control group.

Clinical Trial Description

With economic development, procreation delays have resulted in more women seeking medical help for infertility treatment. Because the quality and quantity of oocytes are affected by physiological age, despite advances in assisted reproductive technology (ART), managing infertility in women with poor ovarian response (POR) remains a daily challenge for physicians. Adult mesenchymal stromal cell (MSC) therapy has gained particular interest in recent years because it may provide a supportive microenvironment for oocyte development from quiescent primordial follicles. Human MSC transplantation has been shown in preclinical studies to host ovaries and restore their function and structure premature ovarian failure (POF) animal models. Because of their encouraging characteristics such as ease of access, high availability, monthly repeatability of sampling, less ethical considerations, lack of tumor-causing potential, protected property, and significant trans-differentiation capacity, endometrial-derived stromal cells have been considered in a wide range of studies since 2007. Menstrual blood-derived stromal cells (MenSCs), on the other hand, are derived from endometrial tissue and can be collected in a non-invasive manner, making them especially useful in the treatment of reproductive disorders. The investigators attempted to assess the safety and efficacy of intraovarian injection of MenSCs for the treatment of infertility in POR patients based on this evidence. The results of this clinical trial's phases I and II indicated that Men-MSCs could be considered as a potential treatment to restore the fertility capability of POR women. Based on these findings, the investigators have designed a Phase III controlled trial of autologous MenSC therapy for patients with POR. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05703308
Study type	Interventional
Source	Avicenna Research Institute
Contact
Status	Completed
Phase	Phase 3
Start date	June 21, 2020
Completion date	October 22, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05969574` - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting	`NCT05358483` - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting	`NCT05969795` - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support	Phase 1
Recruiting	`NCT06051201` - Innovation for Small-scale Experiments: ReceptIVFity Test	N/A
Completed	`NCT03177538` - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders	Phase 4
Completed	`NCT03638856` - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy	N/A
Completed	`NCT04052464` - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn	`NCT04753736` - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC	N/A
Completed	`NCT03349905` - Deferred Versus Fresh Embryo Transfers	N/A
Completed	`NCT05076981` - Progesterone Levels During Ovulation and Luteal Phase
Completed	`NCT04096027` - Cabergoline Before or After Oocyte Collection for Follicular Resolution	Phase 4
Recruiting	`NCT05980091` - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.	Phase 1
Terminated	`NCT01933633` - Improved Fertility After Exercise in Overweight/Obese Women	N/A
Completed	`NCT01202656` - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)	Phase 1/Phase 2
Terminated	`NCT01202643` - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF	Phase 1/Phase 2
Completed	`NCT01408615` - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation	`NCT05698550` - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET	Phase 3
Not yet recruiting	`NCT03910582` - Personalized FET in RIF Patients With Displaced Dating	N/A
Completed	`NCT05440019` - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed	`NCT05130125` - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.